Serum 1,5-Anhydroglucitol Identifies Residual Mortality Risk Beyond Time in Range in Type 2 Diabetes: A Cohort Study.

During follow-up, 522 all-cause deaths and 181 cardiovascular deaths occurred.

Adding 1,5-AG improved traditional risk prediction in the former subgroup.

Compared with 1,5-AG, continuous glucose monitoring-derived glycemic variability indices such as mean amplitude of glycemic excursions, coefficient of variation, and standard deviation of glucose showed no significant association with mortality.